3,241
Participants
Start Date
June 30, 2006
Primary Completion Date
October 31, 2008
Study Completion Date
March 31, 2009
Otamixaban (XRP0673)
intravenous administration
unfractionated heparin
intravenous administration
eptifibatide
intravenous administration
Sanofi-Aventis Administrative Office, Bridgewater
Sanofi-Aventis Administrative Office, Buenos Aires
Sanofi-Aventis Administrative Office, Vienna
Sanofi-Aventis Administrative Office, São Paulo
Sanofi-Aventis Administrative Office, Sofia
Sanofi-Aventis Administrative Office, Laval
Sanofi-Aventis Administrative Office, Santiago
Sanofi-Aventis Administrative Office, Santiago de Cali
Sanofi-Aventis Administrative Office, Zagreb
Sanofi-Aventis Administrative Office, Prague
Sanofi-Aventis Administrative Office, Hørsholm
Sanofi-Aventis Administrative Office, Tatari
Sanofi-Aventis Administrative Office, Helsinki
Sanofi-Aventis Administrative Office, Paris
Sanofi-Aventis Administrative Office, Berlin
Sanofi-Aventis Administrative Office, Athens
Sanofi-Aventis Administrative Office, Budapest
Sanofi-Aventis Administrative Office, Mumbai
Sanofi-Aventis Administrative Office, Netanya
Sanofi-Aventis Administrative Office, Milan
Sanofi-Aventis Administrative Office, Kuala Lumpur
Sanofi-Aventis Administrative Office, México
Sanofi-Aventis Administrative Office, Gouda
Sanofi-Aventis Administrative Office, Warsaw
Sanofi-Aventis Administrative Office, Porto Salvo
Sanofi-Aventis Administrative Office, Bucharest
Sanofi-Aventis Administrative Office, Moscow
Sanofi-Aventis Administrative Office, Singapore
Sanofi-Aventis Administrative Office, Bratislava
Sanofi-Aventis Administrative Office, Midrand
Sanofi-Aventis Administrative Office, Seoul
Sanofi-Aventis Administrative Office, Barcelona
Sanofi-Aventis Administrative Office, Geneva
Sanofi-Aventis Administrative Office, Taipei
Sanofi-Aventis Administrative Office, Bangkok
Sanofi-Aventis Administrative Office, Istanbul
Lead Sponsor
Sanofi
INDUSTRY